Targeted methylation of the Epithelial Cell Adhesion Molecule (EpCAM) promoter to silence its expression in ovarian cancer cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Nunna, Suneetha ^a   Reinhardt, Richard ^b   Ragozin, Sergey ^a   Jeltsch, Albert ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b Max Planck Genomzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; METHYLTRANSFERASE; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA ISOLATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CANCER; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84900412888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087703     Document Type: Article

References (66)

1. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
2. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, et al. (2013) New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. Biomed Res Int 2013: 852839.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30. (Pubitemid 40310185)
4. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10. (Pubitemid 30439309)
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
6. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, et al. (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189: 1120-1127. (Pubitemid 37373908)
7. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43. (Pubitemid 43048949)
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
9. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, et al. (2002) Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8: 2246-2252. (Pubitemid 34753597)
10. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, et al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921.
11. van der Gun BT, de Groote ML, Kazemier HG, Arendzen AJ, Terpstra P, et al. (2011) Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. Br J Cancer 105: 312-319.
12. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, et al. (2004) Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10: 4427-4436. (Pubitemid 38878885)
13. Spizzo G, Gastl G, Obrist P, Fong D, Haun M, et al. (2007) Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett 246: 253-261. (Pubitemid 44959395)
14. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, et al. (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232.
15. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) EpCAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437-446. (Pubitemid 24135956)
16. Thiery JP (1996) The saga of adhesion molecules. J Cell Biochem 61: 489-492.
17. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV (2003) The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139-2148. (Pubitemid 37466457)
18. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, et al. (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64: 415-420.
19. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, et al. (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128. (Pubitemid 38133932)
20. Maetzel D, Denzel S, Mack B, Canis M, Went P, et al. (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11: 162-171.
21. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, et al. (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758. (Pubitemid 39093020)
22. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, et al. (2006) Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103: 483-488. (Pubitemid 44602156)
23. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, et al. (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824. (Pubitemid 39095582)
24. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, et al. (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136. (Pubitemid 38619694)
25. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35: 463-474.
26. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423. (Pubitemid 46215211)
27. Simon M, Stefan N, Pluckthun A, Zangemeister-Wittke U (2013) Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin Drug Deliv 10: 451-468.
28. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, et al. (2003) Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol 129: 341-348. (Pubitemid 36963196)
29. Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2: 129-136.
30. Frampton JE (2012) Catumaxomab: in malignant ascites. Drugs 72: 1399-1410.
31. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36: 458-467.
32. Wimberger P, Heubner M, Lindhofer H, Jager M, Kimmig R, et al. (2009) Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res 29: 1787-1791.
33. Bokemeyer C (2010) Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 10: 1259-1269.
34. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, et al. (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102: 991-998.
35. Schwartzberg LS (2001) Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 40: 17-24.
36. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, et al. (2006) A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 42: 2530-2538. (Pubitemid 44442943)
37. Gommans WM, McLaughlin PM, Lindhout BI, Segal DJ, Wiegman DJ, et al. (2007) Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol Carcinog 46: 391-401. (Pubitemid 46744459)
38. van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, et al. (2013) Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer. Br J Cancer 108: 881-886.
39. Law JA, Jacobsen SE (2010) Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet 11: 204-220.
40. Jurkowska RZ, Jurkowski TP, Jeltsch A (2011) Structure and function of mammalian DNA methyltransferases. Chembiochem 12: 206-222.
41. Cedar H, Bergman Y (2012) Programming of DNA methylation patterns. Annu Rev Biochem 81: 97-117.
42. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
43. Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476. (Pubitemid 351693975)
44. Tai KY, Shiah SG, Shieh YS, Kao YR, Chi CY, et al. (2007) DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 26: 3989-3997.
45. van der Gun BT, Wasserkort R, Monami A, Jeltsch A, Rasko T, et al. (2008) Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation. Int J Cancer 123: 484-489. (Pubitemid 351842037)
46. Jeltsch A, Jurkowska RZ, Jurkowski TP, Liebert K, Rathert P, et al. (2007) Application of DNA methyltransferases in targeted DNA methylation. Appl Microbiol Biotechnol 75: 1233-1240. (Pubitemid 46976679)
47. Jurkowska RZ, Jeltsch A (2010) Silencing of gene expression by targeted DNA methylation: concepts and approaches. Methods Mol Biol 649: 149-161.
48. de Groote ML, Verschure PJ, Rots MG (2012) Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res 40: 10596-10613.
49. van der Gun BT, Maluszynska-Hoffman M, Kiss A, Arendzen AJ, Ruiters MH, et al. (2010) Targeted DNA methylation by a DNA methyltransferase coupled to a triple helix forming oligonucleotide to down-regulate the epithelial cell adhesion molecule. Bioconjug Chem 21: 1239-1245.
50. Bogdanove AJ, Voytas DF (2011) TAL effectors: customizable proteins for DNA targeting. Science 333: 1843-1846.
51. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, et al. (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39: e82.
52. Gaj T, Gersbach CA, Barbas CF, 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31: 397-405.
53. Choo Y, Klug A (1994) Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. Proc Natl Acad Sci U S A 91: 11163-11167. (Pubitemid 24349646)
54. Choo Y, Sanchez-Garcia I, Klug A (1994) In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372: 642-645.
55. Rebar EJ, Pabo CO (1994) Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. Science 263: 671-673. (Pubitemid 24076291)
56. Jamieson AC, Kim SH, Wells JA (1994) In vitro selection of zinc fingers with altered DNA-binding specificity. Biochemistry 33: 5689-5695. (Pubitemid 24184569)
57. Wu H, Yang WP, Barbas CF, 3rd (1995) Building zinc fingers by selection: toward a therapeutic application. Proc Natl Acad Sci U S A 92: 344-348.
58. Liu Q, Segal DJ, Ghiara JB, Barbas CF, 3rd (1997) Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A 94: 5525-5530. (Pubitemid 27241802)
59. Xu GL, Bestor TH (1997) Cytosine methylation targetted to pre-determined sequences. Nat Genet 17: 376-378.
60. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, et al. (2007) Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res 35: 100-112. (Pubitemid 46189835)
61. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, et al. (2012) Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 7: 350-360.
62. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, et al. (2013) Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol 425: 479-491.
63. Zhang Y, Rohde C, Tierling S, Stamerjohanns H, Reinhardt R, et al. (2009) DNA methylation analysis by bisulfite conversion, cloning, and sequencing of individual clones. Methods Mol Biol 507: 177-187.
64. Rohde C, Zhang Y, Reinhardt R, Jeltsch A (2010) BISMA - fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. BMC Bioinformatics 11: 230.
65. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, et al. (2012) Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 40: 6725-6740.
66. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006. (Pubitemid 34662293)